Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 78 points (0.5%) at 16,438 as of Thursday, March 6, 2014, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,775 issues advancing vs. 1,148 declining with 152 unchanged. The Drugs industry currently is unchanged today versus the S&P 500, which is up 0.4%. Top gainers within the industry include Teva Pharmaceutical Industries ( TEVA), up 1.6%, AbbVie ( ABBV), up 1.2%, Novartis ( NVS), up 1.2%, Merck ( MRK), up 1.0% and Amgen ( AMGN), up 0.5%. On the negative front, top decliners within the industry include Valeant Pharmaceuticals International ( VRX), down 2.3%, Mylan ( MYL), down 1.5% and Actavis ( ACT), down 1.5%. TheStreet would like to highlight 3 stocks pushing the industry higher today: 3. Sanofi ( SNY) is one of the companies pushing the Drugs industry higher today. As of noon trading, Sanofi is up $0.52 (1.0%) to $52.32 on light volume. Thus far, 277,815 shares of Sanofi exchanged hands as compared to its average daily volume of 1.7 million shares. The stock has ranged in price between $52.18-$52.48 after having opened the day at $52.40 as compared to the previous trading day's close of $51.80. Sanofi researches, develops, manufactures, and markets healthcare products. The company operates in Pharmaceuticals, Human Vaccines, and Animal Health segments. Sanofi has a market cap of $138.5 billion and is part of the health care sector. Shares are down 3.1% year-to-date as of the close of trading on Wednesday. Currently there are 2 analysts who rate Sanofi a buy, no analysts rate it a sell, and 4 rate it a hold. TheStreet Ratings rates Sanofi as a buy. The company's strengths can be seen in multiple areas, such as its increase in net income, revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins and growth in earnings per share. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Sanofi Ratings Report now. 3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.